TY - JOUR
T1 - Neuroleptic-like effects of γ-hydroxybutyrate
T2 - Interactions with haloperidol and dizocilpine
AU - Sevak, Rajkumar J.
AU - France, Charles P.
AU - Koek, Wouter
N1 - Funding Information:
This work was supported by USPHS grant DA14986 and RCA grant DA00211 to CPF.
PY - 2004/1/12
Y1 - 2004/1/12
N2 - γ-Hydroxybutyrate (GHB) is a drug of abuse with multiple mechanisms of action. Consistent with its ability to modulate dopaminergic systems, GHB reportedly shares behavioral effects with neuroleptics and interacts with them in a synergistic manner. Here, we examined the ability of GHB and haloperidol to induce catalepsy and to affect operant responding. When given alone, both compounds induced catalepsy and decreased response rate. When given together, however, they produced these effects in an additive manner. This is further evidence that GHB has neuroleptic-like effects, but suggests that GHB interacts additively, not synergistically, with neuroleptics. The mechanisms involved in GHB- and haloperidol-induced catalepsy are different because the N-methyl-D-aspartate (NMDA) receptor antagonist, dizocilpine (MK-801), attenuated the cataleptic effects of haloperidol, but enhanced those of GHB. The latter finding suggests that other NMDA receptor antagonists (e.g., the drugs of abuse - phencyclidine and ketamine) may also interact synergistically with GHB.
AB - γ-Hydroxybutyrate (GHB) is a drug of abuse with multiple mechanisms of action. Consistent with its ability to modulate dopaminergic systems, GHB reportedly shares behavioral effects with neuroleptics and interacts with them in a synergistic manner. Here, we examined the ability of GHB and haloperidol to induce catalepsy and to affect operant responding. When given alone, both compounds induced catalepsy and decreased response rate. When given together, however, they produced these effects in an additive manner. This is further evidence that GHB has neuroleptic-like effects, but suggests that GHB interacts additively, not synergistically, with neuroleptics. The mechanisms involved in GHB- and haloperidol-induced catalepsy are different because the N-methyl-D-aspartate (NMDA) receptor antagonist, dizocilpine (MK-801), attenuated the cataleptic effects of haloperidol, but enhanced those of GHB. The latter finding suggests that other NMDA receptor antagonists (e.g., the drugs of abuse - phencyclidine and ketamine) may also interact synergistically with GHB.
KW - Catalepsy
KW - Dizocilpine
KW - GHB (γ-Hydroxybutyrate)
KW - Haloperidol
KW - Synergism
UR - http://www.scopus.com/inward/record.url?scp=0346687637&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0346687637&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2003.10.045
DO - 10.1016/j.ejphar.2003.10.045
M3 - Article
C2 - 14729119
AN - SCOPUS:0346687637
SN - 0014-2999
VL - 483
SP - 289
EP - 293
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 2-3
ER -